



*A Member of the Roche Group*

600 Massachusetts Ave. NW, Suite 300  
Washington, DC 20001  
Phone: (202) 296-7272  
Fax: (202) 296-7290

February 9, 2026

Oregon Prescription Drug Affordability Board  
350 Winter Street NE  
Salem, OR 97309-0405  
pdab@dcbs.oregon.gov

**Re: 2026 Preliminary Drug List - Removal of HEMLIBRA®**

Dear Members of the Oregon Prescription Drug Affordability Board:

To streamline your ongoing deliberations to narrow your preliminary drug list to a subset list for review in 2026, we urge you to immediately remove drugs that are ineligible for an affordability review under Oregon statute and the Board's regulations. Taking this action will provide greater clarity for the Board and its stakeholders prior to the Board's February meeting.

Genentech's medicine, HEMLIBRA® (emicizumab-kxwh), is solely designated by the Secretary of the Food and Drug Administration as a drug for a rare disease or condition under 21 U.S.C. 360bb. Per ORS 646A.694 (2), such a drug is not eligible to be subject to an affordability review by the Board.<sup>1</sup> HEMLIBRA is an orphan-designated, FDA-approved medicine for the treatment of Hemophilia A, a rare disease. HEMLIBRA does not have any additional FDA-approved indications.

We respectfully ask the Board to promptly and publicly remove HEMLIBRA from the Board's preliminary drug list. If you have any questions or wish to discuss our comments, please contact Tim Layton, Director of State Government Affairs at [layton.timothy@gene.com](mailto:layton.timothy@gene.com) or (206) 403-8224.

Sincerely,

Mary Wachter, RN  
Executive Director  
State & Local Government Affairs

---

<sup>1</sup> Oregon Revised Statutes. ORS 646A.694 (2). [https://www.oregonlegislature.gov/bills\\_laws/ors/ors646a.html](https://www.oregonlegislature.gov/bills_laws/ors/ors646a.html)